What is NVNO (NVNO) stock price today?

NVNO (NVNO) is currently trading at $11.15, up 4.21% today.

What is NVNO P/E ratio?

NVNO's P/E ratio is -0.31. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is NVNO return on equity (ROE)?

NVNO's return on equity (ROE) is -60.65%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is NVNO's market cap?

NVNO has a market capitalization of $184008.

NASDAQ · Medical - Devices

NVNO (NVNO) Stock

$11.15 +4.21% NASDAQ: NVNO Healthcare

Valuation

Metric	Value
Price	$11.15
Market Cap	$184008
P/E Ratio	-0.31
P/B Ratio	0.28
P/S Ratio	0.00
EPS (TTM)	$-33.06
52-Week High	$196.70
52-Week Low	$8.67
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-60.65%
ROA	-37.51%
ROCE	-75.00%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.03
Current Ratio	14.50

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-17.0M	$-25.0M	$-25.0M	$-24.0M	$-21.0M
Net Profit	$-17.0M	$-25.0M	$-24.0M	$-22.0M	$-19.0M
EPS	$-2327.50	$-2695.00	$-2339.75	$-1555.75	$-33.06
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$58.0M	$42.0M	$49.0M	$45.0M	$30.0M
Total Liabilities	$3.0M	$3.0M	$2.0M	$3.0M	$2.0M
Cash	$55.0M	$5.0M	$4.0M	$2.0M	$3.0M
Borrowings	$2.0M	$2.0M	$1.0M	$1.0M	$1.0M

Latest News

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment ACCESS Newswire · Jul 15, 2026 enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial ACCESS Newswire · Jul 7, 2026 enVVeno Medical to Present in the Webull Corporate Connect Webinar Series ACCESS Newswire · Jun 22, 2026 enVVeno Medical to Participate in the Virtual Investor Closing Bell Series ACCESS Newswire · Jun 2, 2026 enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment ACCESS Newswire · May 12, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-12.0M	$-16.0M	$-19.0M	$-17.0M	$-16.0M
Investing Cash Flow	$-1.0M	$-35.0M	$-8.0M	$1.0M	$16.0M
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$45.0M	$-50.0M	$-1.0M	$-2.0M	$1.0M
Free Cash Flow	$-12.0M	$-16.0M	$-19.0M	$-17.0M	$-16.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	0.89
FCF Yield	-8749.48%
Quick Ratio	11.89
Interest Coverage	—
Return 1Y	-92.55%
Return 3Y	-90.27%
Return 5Y	-94.63%

Ownership

Insiders Held13.38%

Institutions Held25.62%

Institutions Float Held29.58%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$313.33	+0.29%	37.72	$4.60T	0.34%
MSFTMicrosoft Corporation	$499.99	+0.03%	22.95	$3.71T	0.94%
GOOGLAlphabet Inc.	$354.30	-0.96%	27.68	$4.29T	0.23%
AMZNAmazon.com, Inc.	$274.48	+0.82%	28.76	$2.95T	0.00%
METAMeta Platforms, Inc.	$592.10	+0.37%	21.47	$1.51T	0.35%

About NVNO

NVNO is led by CEO Robert A. Berman, employs 37 people, headquartered in US, publicly traded since 2018.

NVNO stock trades at $11.15 with a market capitalization of $184008. The stock is valued at a price-to-earnings (P/E) ratio of -0.31, price-to-book of 0.28, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $8.67 and $196.70, and currently trades 94.3% below its 52-week high.

On profitability, NVNO generates a return on equity (ROE) of -60.65%, return on capital employed of -75.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides